Table 4.
Incidence and type of serious adverse events
Variable | Placebo group (n = 29) | Selenium group (n = 31) | P value |
At least one serious adverse event | 18 (62) | 25 (81) | 0.111 |
Type of event | |||
Respiratory failure | 1 (3) | 5 (16) | 0.196 |
Cardiac failure | 1 (3) | 1 (3) | 1.000 |
Renal failure | 1 (3) | 0 (0) | 0.483 |
Ischaemic event | 6 (21) | 2 (7) | 0.134 |
Intracranial haemorrhage | 1 (3) | 1 (3) | 1.000 |
Refractory shock | 6 (21) | 5 (16) | 0.648 |
Multiorgan failure | 4 (14) | 10 (32) | 0.091 |
Superinfection | 2 (7) | 1 (3) | 0.606 |
Othersa | 0 (0) | 2 (7) | 0.492 |
Data presented as n (%). aIncludes one thrombocytopenia and one radial artery pseudoaneurysm.